checkAd

     157  0 Kommentare Telesis Bio Announces First Commercial Shipment of BioXp NGS Library Prep Kit - Seite 2

    Telesis Bio, the Telesis Bio logo, Gibson Assembly, and BioXp are trademarks of Telesis Bio Inc.

    About Novel Biotechnology Inc.

    Novel Biotechnology Inc. is on a mission to develop disruptive platforms that address unmet needs in the life sciences and pharmaceutical domains. Their focus is on developing new solutions for manufacturing plasmid DNA, a critical starting material for gene therapy, cell engineering, mRNA therapy and vaccine applications. They are developing a platform that is safe, scalable, adaptable to different plasmid backbones and payloads, has improved product quality, and is many times more productive than existing systems. Through their services business, they are currently offering plasmid DNA manufacturing services to a growing base of customers.

    Forward-Looking Statements
    This press release contains forward-looking statements. All statements other than statements of historical facts contained herein are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements include statements and guidance regarding Telesis Bio’s future financial performance as well as statements regarding the future release and success of new and existing products and services. Such statements are based on current assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. These risks and uncertainties, many of which are beyond our control, include risks described in the section entitled Risk Factors and elsewhere in our Quarterly Report on Form 10-Q, which was filed with the Securities and Exchange Commission on May 12, 2023. These forward-looking statements speak only as of the date hereof and should not be unduly relied upon. Telesis Bio disclaims any obligation to update these forward-looking statements.

    Contact:
    Jen Carroll
    Vice President of Investor Relations
    jen.carroll@telesisbio.com


    Seite 2 von 2



    globenewswire
    0 Follower
    Autor folgen

    Verfasst von globenewswire
    Telesis Bio Announces First Commercial Shipment of BioXp NGS Library Prep Kit - Seite 2 New Kit Enables Automation of NGS Library Prep on the BioXp System Further Expanding the Utility, Speed, and Impact of the BioXp Automated Molecular Biology WorkstationSAN DIEGO, May 18, 2023 (GLOBE NEWSWIRE) - Telesis Bio Inc. (NASDAQ: TBIO), a …